Skip to main content
. 2023 Jun 30;14:1199173. doi: 10.3389/fimmu.2023.1199173
(NK) natural killer
(TAMs) tumor associated macrophages
(DDS) drug delivery system
(CTLs) cytotoxic T lymphocytes
(DAMPs) damage associated molecular patterns
(PRRs) pattern recognition receptors
(APCs) antigen-presenting cells
(DCs) dendritic cells
(TNF) tumor necrosis factor
(CAR)-engineered T cells chimeric antigen receptor
(CAR)-engineered T cells (CAR-T) chimeric antigen receptor
(TCRs) T cell receptors
(MHC) major histocompatibility complex
(PD-1) programmed cell death protein 1
(PD-L1) programmed cell death ligand 1
(FasL) Fas ligand
(CD95L) FasL
(CD95) Fas
(IFN) interferon
(CTLA-4) cytotoxic T-lymphocyte antigen 4
(aAPC) artificial APCs
(pMHC-I) peptide-loaded major histocompatibility complex Class I
(αCD28) anti-CD28
(naAPCs) nanodimensional artificial antigen presenting cells
(CHA) chlorogenic acid
(SMEDDS) self-microemulsifying drug delivery systems
(STING) stimulator of interferon genes
(MUSIC) microbubble-assisted ultrasound-guided immunotherapy of cancer
(cGAMP) cyclic guanosine monophosphate-adenosine monophosphate
(TNFRSF5) tumor necrosis factor receptor superfamily member 5
(TNFRSF9) tumor necrosis factor receptor superfamily member 9
(TRAF) TNF receptor-associated factor
(MAPK) mitogen-activated protein kinase
(IL-2) interleukin 2
(Gal-1) galectin-1
(VISTA) V-domain Ig suppressor of T cell activation
(TIGIT) T cell immunoreceptor with immunoglobulin and ITIM domains
(GITR) glucocorticoid-induced TNFR-related protein
(TNFRSF4) tumor necrosis factor receptor superfamily member 4
(PD-L2) programmed cell death ligand 2
(CpG-ODN) cytosine-phosphate-guanosine oligodeoxynucleotides
(ssDNA) single-stranded DNA
nanoparticles (NPs)
(TGMS) nanoparticles triglycerol monostearate
(TGMS NPs)
(MMPs) matrix metalloproteinases
(TME) tumor microenvironment
(GBM) glioblastoma multiforme
(TNFRSF18, CD357) tumor necrosis factor receptor superfamily 18
(ESCC) esophageal squamous cell carcinoma
(PLGA) Poly (lactic-co-glycolic acid)
(ITAM) immunoreceptor tyrosine-based activation motif
(LFA-1) lymphocyte function-associated antigen-1
(Mac-1) macrophage-1 antigen
(VLA-4; CD49d/CD29) integrin very late antigen-4
(TNF)-related apoptosis-inducing ligand tumor necrosis factor
(TRAIL)
(GSDMB) gasdermin B
(NKSF) Natural killer cell stimulatory factor
(TGF-β) transforming growth factor-β
(PG) prostaglandins
(KIRs) killer immunoglobulin-like receptors
(ICI) immune checkpoint inhibitors
(TIM-3) T cell immunoglobulin and mucin-containing molecule 3
(LAG-3) lymphocyte activation gene-3
(EGFR) epidermal growth factor receptor
(AML) acute myeloid leukemia
(nano-TriNKE) nanoparticle-based trispecific NK cell engager
(PEG-PLGA) Poly (ethylene glycol)–block-poly(lactide-co-glycolide)
(NKCE) NK cell engager
(HR-MDS) high risk-myelodysplastic syndrome
(oNK) oNK cell line
(BiKE) NK cell-targeted bispecific antibodies
(MRD) minimal residual disease
(NSCLC) non-small-cell lung cancer
(CSF-1) Colony stimulating factor 1
(LPS) Lipopolysaccharide
(GM-CSF) granulocyte-macrophage colony-stimulating factor
(ROS) reactive oxygen species
(NO) nitric oxide
(Th1) type 1 helper T
(HIF) hypoxia inducible factor
(VEGF) vascular endothelial growth factor
(FRβ) Folate receptors β
(AuNPs) gold nanoparticle
(MARCO) macrophage receptor with collagen structure
(TLR2) toll-like receptor 2
(cGAS-STING) the cyclic GMP-AMP synthase-stimulator of interferon genes
(cGAMP) 2’3’ cyclic guanosine monophosphate-adenosine monophosphate
(EPR) enhanced permeability and retention